Jose Antonio Maza LarreaNational Institute of Cardiology, Mexico
Title: Evaluation of the safety profile of the drug lopinavir/ritonavir (Lpv/r) is suspected or confirmed COVID-19 patients
The new SARS-CoV-2 is the causal agent for COVID-19. The World Health Organization (WHO) referenced the use of lopinavir/ritonavir (Lpv/r), which is a protease inhibitor of human inmunodeficiency virus (HIV-1). The Clinical trial by Cao et al. identified that the use of Lpv/r has not been associated with any increase of adverse drug reactions within compared to the standard of care. Materials and methods: Pharmacovigilance retrospective study of patients suspected or confirmed with COVID-19 in a 3rd level hospital in Mexico City from April, 01 2020 to July, 30 2020. Results: Lopinavir/ritonavir treatment was prescribed 140 patients from which 91 patients completed the treatment, while 50 patients did not completed the treatment. The cause suspensions were: patient discharge for improvement (11 cases), deaths (10 cases) and start of ruxolitinib (9 cases). In addition, were identify 8 adverse drug reaction from which 5 were associated to gastrointestinal disorders (diarrhea) and 3 hepatobiliary disorders (hypertransaminasemia). Conclusion: The safety profile of the Lpv/r demonstrated consistency with the observations of previous studies in relation to gastrointestinal and hepatic adverse events, which were related to drug-drug interaction, so we suggest a pharmacotherapeutic monitoring to identify them as well as adverse drug reactions due to Lpv/r.
Graduated as Md Doctor form Westhil University and as Pharmacist form the Faculty of Chemical at La Salle University. He volunteered at the Mexican Red Cross as an emergency medical technician. Worked in the pharmaceutical industry, as a regulatory affairs analyst for Johnson & Johnson. Collaborated as a drug safety consultant at the Women's Military Hospital in México City. And completing his medical internship at the Central Military Hospital and his social service in the rotating program at Mexico’s City Secretary of Health. He is currently the Chief of Clinical Pharmacology and head of the Institutional Center for Pharmacovigilance at the National Institute of Cardiology Ignacio Chávez in México City. He is part of the International Society of Pharmacovigilance, collaboration in the Special investigation groups for Vaccines and Risk Communication. Participates as a member of the Latin American Pharmacovigilance Network and has de direction of Clinical Pharmacology and Pharmacovigilance at the Mexican Pharmaceutic Association.